UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 3, pp. 225 - 231
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Pyrazoles - therapeutic use | Ischemic Attack, Transient - drug therapy | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Stroke - drug therapy | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Aged | Aspirin - therapeutic use | Pyridones - therapeutic use | Stroke (Disease) | Care and treatment | Aspirin | Ischemia | Atrial fibrillation | Abnormalities | Clinical trials | Muscle contraction | Index Medicus | Stroke | Fibrillation | Transient ischemic attack | Regression analysis | Age | Bleeding | Embolism | Risk factors | Vitamin K
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 15, pp. 1389 - 1398
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Thrombectomy - adverse effects | Combined Modality Therapy - adverse effects | Coronary Thrombosis - therapy | Myocardial Infarction - complications | Myocardial Infarction - therapy | Stroke - etiology | Coronary Thrombosis - complications | Cardiovascular Diseases - mortality | Electrocardiography | Microvessels | Female | Aged | Heart Failure - etiology | Percutaneous Coronary Intervention - adverse effects | Care and treatment | Usage | Patient outcomes | Cardiac patients | Surgery | Health aspects | Heart attack | Risk factors | Embolism | Myocardial infarction | Cerebral infarction | Medical research | Heart attacks | Heart surgery | Clinical trials | Thrombosis | Evidence-based medicine | Blood clots | Perfusion | Coronary vessels | Implants | Embolization | Death | Microvasculature | Cardiovascular diseases | Heart diseases | Heart failure | Stroke | Funding | Mortality | Catheters | Bailouts | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2019, Volume 73, Issue 21, pp. 2769 - 2772
cardiovascular events | clinical trial stopping guidelines | clinical trials | major bleeding | data monitoring | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiovascular Diseases - prevention & control | Fibrinolytic Agents - therapeutic use | Humans | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Rivaroxaban - therapeutic use | Cardiac arrhythmia | Anticoagulants | Stroke | Aspirin | Warfarin | Effectiveness | Hemorrhage | Patients | Bleeding | Embolism | Regulatory approval | Fibrillation | Safety | Acute coronary syndromes | Cardiovascular diseases | Monitoring | Vitamin K
Journal Article
The American heart journal, ISSN 0002-8703, 2014, Volume 167, Issue 3, pp. 315 - 321.e1
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Microcirculation | Myocardial Infarction - therapy | Prospective Studies | Percutaneous Coronary Intervention - methods | Humans | Thrombectomy - methods | Treatment Outcome | Combined Modality Therapy | Suction - methods | Transluminal angioplasty | Clinical trials | Care and treatment | Cardiac patients | Heart attack | Heart failure | Enzymes | Stroke | Heart attacks | Medical imaging | Mortality | Thrombosis | Clinical outcomes | Catheters | Blood clots | Hypotheses | Blood pressure | Cardiology | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2019, Volume 73, Issue 18, pp. 2243 - 2250
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Correlation of Data | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Renal Insufficiency, Chronic - complications | Peripheral Arterial Disease - complications | Risk Adjustment - methods | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Fibrinolytic Agents - adverse effects | Rivaroxaban - adverse effects | Aspirin - adverse effects | Female | Renal Insufficiency, Chronic - diagnosis | Myocardial Infarction - etiology | Outcome and Process Assessment, Health Care | Glomerular Filtration Rate | Double-Blind Method | Peripheral Arterial Disease - drug therapy | Coronary Artery Disease - drug therapy | Drug Therapy, Combination - methods | Coronary Artery Disease - complications | Aged | Fibrinolytic Agents - administration & dosage | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Myocardial infarction | Anticoagulants | Cerebral infarction | Aspirin | Stroke | Renal function | Heart attacks | Health risks | Cardiovascular disease | Bleeding | Glomerular filtration rate | Confidence intervals | Cost-benefit analysis | Vascular diseases | Ischemia | Coronary vessels | Diuretics | Kidney diseases | Secondary analysis | Nonsteroidal anti-inflammatory drugs | Health risk assessment
Journal Article
Age and ageing, ISSN 0002-0729, 01/2016, Volume 45, Issue 1, pp. 77 - 83
Stroke | Anticoagulation | Elderly | Atrial fibrillation | Age | Apixaban | Life Sciences & Biomedicine | Geriatrics & Gerontology | Science & Technology | Pyrazoles - therapeutic use | Prospective Studies | Age Factors | Humans | Stroke - diagnosis | Male | Time Factors | Aspirin - adverse effects | Atrial Fibrillation - mortality | Aged, 80 and over | Female | Aspirin - therapeutic use | Atrial Fibrillation - diagnosis | Pyrazoles - adverse effects | Stroke - prevention & control | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Atrial Fibrillation - blood | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Care and treatment | Patients | Health aspects | Risk factors | Elderly people | Cardiac arrhythmia | High risk | Clinical trials | Strokes | Antagonists | Acetylsalicylic acid | Hemorrhage | Bleeding | Clinical outcomes | Fibrillation | Older people | Hostility | Safety | Vitamin K | Aspirin | Efficacy | Embolism | Haemorrhage | Geriatrics | Index Medicus
Journal Article
European heart journal, ISSN 0195-668X, 2013, Volume 34, Issue 3, pp. 170 - 176
Stroke risk score | Antithrombotic treatment | Atrial fibrillation | Severity of Illness Index | Stroke - prevention & control | Anticoagulants - administration & dosage | Risk Assessment | Administration, Oral | Atrial Fibrillation - drug therapy | Humans | Kaplan-Meier Estimate | Male | Ticlopidine - analogs & derivatives | Aspirin - administration & dosage | Thromboembolism - prevention & control | Platelet Aggregation Inhibitors - administration & dosage | Brain Ischemia - diagnosis | Ticlopidine - administration & dosage | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Index Medicus
Journal Article
European heart journal, ISSN 0195-668X, 02/2015, Volume 36, Issue 5, pp. 7 - 287
Stroke | Paroxysmal | Permanent | Atrial fibrillation | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Humans | Risk Factors | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Male | Brain Ischemia - prevention & control | Brain Ischemia - etiology | Stroke - etiology | Fibrinolytic Agents - therapeutic use | Sex Distribution | Female | Aged | Aspirin - therapeutic use | Embolism - etiology | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2019, Volume 74, Issue 12, pp. 1519 - 1528
coronary artery disease | dual pathway | aspirin | rivaroxaban | bleeding | peripheral artery disease | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Severity of Illness Index | Humans | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Rivaroxaban - adverse effects | Aspirin - adverse effects | Coronary Artery Disease - complications | Factor Xa Inhibitors - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Female | Aged | Hemorrhage - chemically induced | Drug Combinations | Platelet Aggregation Inhibitors - adverse effects | Anticoagulants | Aspirin | Stroke | Transfusion | Mortality | Cardiovascular disease | Gastrointestinal tract | Thrombosis | Bleeding | Clotting | Randomization | Vascular diseases | Hemostasis | Rectum | Hemoglobin | Hemostatics | Thromboembolism | Cardiovascular diseases | Platelets
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2019, Volume 73, Issue 18, pp. 2243 - 2250
Journal Article
European heart journal, ISSN 0195-668X, 2014, Volume 35, Issue 28, pp. 1856 - 1863
Aspirin | Stroke | Atrial fibrillation | Vitamin K antagonists | Bleeding | Apixaban | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Humans | Risk Factors | Atrial Fibrillation - complications | Male | Treatment Outcome | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Fibrinolytic Agents - adverse effects | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Vitamin K - antagonists & inhibitors | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Female | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Pyridones - adverse effects | Pyrazoles - adverse effects | Index Medicus
Journal Article
Neurology, ISSN 0028-3878, 08/2020, Volume 95, Issue 5, pp. e480 - e487
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 09/2019, Volume 157, Issue 3, pp. 682 - 691.e2
Reflux | CVD | Bacteria | Thrombosis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Enterocolitis, Pseudomembranous - microbiology | Pantoprazole - administration & dosage | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Enterocolitis, Pseudomembranous - chemically induced | Rivaroxaban - adverse effects | Proton Pump Inhibitors - administration & dosage | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Female | Cardiovascular Diseases - diagnosis | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Risk Factors | Peripheral Arterial Disease - drug therapy | Treatment Outcome | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peripheral Arterial Disease - diagnosis | Factor Xa Inhibitors - adverse effects | Pantoprazole - adverse effects | Aged | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article